Filing Details
- Accession Number:
- 0001144204-18-015759
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2018-03-20 10:48:44
- Reporting Period:
- 2018-03-15
- Accepted Time:
- 2018-03-20 10:48:44
- Original Submission Date:
- 2018-03-19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1137883 | Brainstorm Cell Therapeutics Inc. | BCLI | Biological Products, (No Disgnostic Substances) (2836) | 207273918 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1699684 | Dr. Ralph Kern | C/O Brainstorm Cell Therapeutics Inc. 1745 Broadway, 17Th Floor New York NY 10019 | Coo And Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-15 | 5,000 | $3.60 | 40,885 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- This Form 4/A is being filed to reflect that this transaction was an open market purchase of the Issuer's securities (on March 19, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d)).
Billionaire Hedge Funds
